

1 **Clinical validation of innovative, low cost, kit-free, RNA processing protocol for RT-PCR**
2 **based COVID-19 testing.**

3
4 Nikhil Shri Sahajpal,¹ Ashis K Mondal,¹ Allan Njau,² Sudha Ananth,¹ Arvind Kothandaraman,³
5 Madhuri Hegde,³ Alka Chaubey,³ Sandeep Padala,⁴ Vamsi Kota,⁴ Kevin Caspary,⁵ Stephen M
6 Tompkins,⁶ Ted Ross,⁶ Aryn M. Rojani,¹ Ravindra Kolhe^{1*}

7
8 ¹ Department of Pathology, Medical College of Georgia, Augusta University, GA, U.S.A.

9 ² Department of Pathology, Aga Khan University Hospital, Nairobi, Kenya.

10 ³ Global Laboratory Services, PerkinElmer, Waltham, USA.

11 ⁴ Department of Medicine, Medical College of Georgia, Augusta University, GA, U.S.A.

12 ⁵ Nuclear Medical Science Officer, 4th WMD CST, GA, U.S.A

13 ⁶ Center for Vaccines and Immunology, University of Georgia, GA, U.S.A.

14

15

16

17 **Running title:** Kit-free RNA extraction for COVID-19 testing

18

19

20

21

22

23 ***Corresponding author**

24 Ravindra Kolhe MD, PhD.

25 Medical College of Georgia| Augusta University.

26 BAE 2576, 1120 15th Street| Augusta, GA 30912

27 Email: rkolhe@augusta.edu

28 P: (706)-721-2771

29 F: (706)-434-6053

30 rkolhe@augusta.edu

31 **Abstract**

32 The current gold-standard molecular diagnosis for COVID-19 is based on a multi-step assay
33 involving RNA-extraction and RT-PCR analysis for the detection of SARS-CoV-2. RNA-
34 extraction step has been a major rate-limiting step in implementing high-throughput screening
35 for COVID-19 during this pandemic. Moreover, clinical laboratories are facing several
36 challenges that include cost, reagents, instrumentation, turn-around time, trained personnel, and
37 supply-chain constraints to efficiently implement and sustain testing. Cognizant of these
38 limitations, we evaluated the extraction-free methods described in the literature and have
39 developed an innovative, simplified and easy protocol employing limited reagents to extract
40 RNA for subsequent RT-PCR analysis. Nasopharyngeal-swab samples were subjected to the
41 following individual conditions: 65°C for 15 minutes; 80°C for 5 minutes; 90°C for 5 minutes or
42 80°C for 1 minute, and processed for direct RT-PCR. These groups were also compared with a
43 supplemental protocol adding isopropanol-ethanol-water elution steps followed by RT-PCR
44 assay. The direct RT-PCR assay did not detect SARS-CoV-2 within the various temperature
45 incubation only groups, whereas, the 90°C for 5 minutes-isopropanol-ethanol-water method was
46 found to be comparable to the FDA-EUA method. Evaluation of the performance metrics for
47 100 clinical samples demonstrated a sensitivity of 94.2% and a specificity of 100%. The limit of
48 detection was ascertained to be ~40 copies/ml by absolute-quantification. The protocol presented
49 for this assay employs limited reagents and yields results with high sensitivity. Additionally, it
50 presents a simplified methodology that would be easier to implement in laboratories in limited
51 resource countries in order to meet the high current COVID-19 testing needs.

52

53 **Introduction**

54 On December 31st 2019, an outbreak of pneumonia of unknown etiology in Wuhan city, China
55 was reported to the World Health Organization (WHO) ([https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4)
56 [source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4), last
57 accessed July 11, 2020). Since then, severe acute respiratory syndrome coronavirus 2 (SARS-
58 CoV-2) has infected more than 111,495,412 individuals across the globe, with at least 535,185
59 COVID-19 related deaths (<https://coronavirus.jhu.edu/map.html>, last accessed June 1, 2020). In
60 an attempt to contain the spread of the disease, multidisciplinary strategies have been launched in
61 different regions of the world, including social distancing, maintaining personal hygiene, testing,
62 contact tracing, quarantine, travel restrictions, and lockdowns (1). Among these strategies, the
63 most critical method adopted to measure and contain its spread is testing for SARS-CoV-2,
64 typically utilizing nasopharyngeal swab specimens (2). Diagnostic testing for SARS-CoV-2 has
65 been under intense scrutiny due to its tremendous, immediate clinical and epidemiologic
66 significance in the current COVID-19 pandemic. The global demand for testing has reached a
67 crisis level, with clearly identifiable regional disparities. At present, RT-PCR based assays are
68 the predicate methods for detecting SARS-CoV-2, targeting selected regions of the virus
69 nucleocapsid (N), envelop (E) or open reading frame (ORF) genes
70 ([https://www.centerforhealthsecurity.org/resources/COVID-19/COVID-19-fact-sheets/200410-](https://www.centerforhealthsecurity.org/resources/COVID-19/COVID-19-fact-sheets/200410-RT-PCR.pdf)
71 [RT-PCR.pdf](https://www.centerforhealthsecurity.org/resources/COVID-19/COVID-19-fact-sheets/200410-RT-PCR.pdf), last accessed July 12, 2020).

72 The RT-PCR based methods employ sophisticated commercial kit based RNA extraction
73 protocols followed by a one-step RT-PCR assay for the detection of the SARS-CoV-2 virus.
74 However, there are several challenges in the implementation and sustainability of this method for
75 COVID-19 testing, especially in resource-limited countries. The technical and financial
76 challenges include the cost of reagents/ kits, equipment, turnaround time, and trained personnel.
77 The RNA extraction step is a bottleneck by virtue of its requirement of expensive kits, a
78 processing time of ~100 minutes with automated instrumentation, and trained personnel to run
79 the protocol. For laboratories that employ manual methods of RNA extraction, this process could
80 take much longer, up to several hours. Further, COVID-19 testing has lagged significantly even
81 in developed countries, owing to the widespread supply chain constraints of these kits.
82 In these circumstances, there is a dire need to identify solutions or alternatives to these
83 limitations and identify methods that can be easily implemented, with simple protocols,

84 minimum reagents, and yet maintaining the high sensitivity standards of the assay. In search of
85 such methods, several preprints have surfaced evaluating RNA extraction-free, RT-PCR
86 protocols. These methods are either based on collecting dry-swabs directly in a small volume of
87 Tris-EDTA (TE) buffer instead of universal transport media (UTM) or aliquotting a small
88 volume of nasopharyngeal swab sample (NPS) for direct RT-PCR for the detection of SARS-
89 CoV-2 (3-6). Both protocols typically employ heat-shock treatment of the samples before
90 proceeding to the RT-PCR step. However, there are several limitations to both these concepts.
91 The dry-swabs collected in TE require immediate processing, which does not seem to be a viable
92 scenario in the present circumstances, as samples are often collected in different locations in
93 large cities or different regions of the state/country and are shipped to laboratories for testing,
94 leading to a turnaround time of 3-7 days. On the other hand, the processing of a small aliquot (3
95 to 10 ul) of the NPS sample for direct RT-PCR assay after heat-shock treatment is likely to yield
96 false-negative results. Thus, we evaluated these methods and formulated a simple and easy
97 protocol employing minimum reagents to extract SARS-CoV-2 RNA for RT-PCR analysis that
98 could be easily implemented in developed and resource limited countries alike.

99 **Materials and Methods**

100 **Samples**

101 Clinical samples (nasopharyngeal swab-NPS samples), previously screened by RT-PCR FDA-
102 EUA approved method (PerkinElmer Inc, USA) were selected for the development and
103 evaluation of an alternate RNA-extraction protocol. A total of one hundred samples, seventy
104 positive and thirty negative samples, were used in this study.

105 **Assay for the detection of SARS-CoV-2 (FDA-EUA Method)**

106 The assay is based on RNA extraction followed by TaqMan-based RT-PCR assay to conduct the
107 *in vitro* transcription of SARS-CoV-2 RNA, DNA amplification, and fluorescence detection
108 (PerkinElmer Inc, USA) (<https://www.fda.gov/media/136407/download>, last accessed June 1,
109 2020). The assay targets specific genomic regions of SARS-CoV-2: nucleocapsid (*N*) gene and
110 *ORF1ab*. The TaqMan probes for the two amplicons are labeled with the FAM and ROX
111 fluorescent dyes, respectively, to generate target-specific signals. The assay includes an RNA
112 internal control (IC, bacteriophage MS2) that serves as an assay control from nucleic acid
113 extraction to fluorescence detection. The IC probe is labeled with VIC fluorescent dye to
114 differentiate its fluorescent signal from the two SARS-CoV-2 targets.

115

116 **RNA extraction and RT-PCR (FDA-EUA Method)**

117 The RNA extraction is semi-automated and occurs in a 96-well plate format. In brief, an aliquot
118 of 300µl from each sample, including positive and negative controls, were added to respective
119 wells of a 96 well plate. To each well, 5µl internal control, 4µl Poly(A) RNA, 10µl proteinase K
120 and 300µl lysis buffer 1 were added. The plate was placed on a semi-automated instrument
121 (Chemagic 360 instrument, PerkinElmer, Inc.) following the manufacturer's protocol. The
122 nucleic acid was extracted in a 96 well plate, with an elution volume of 60µl. From the extraction
123 plate, 40µl of extracted nucleic acid and 20µl of RT-PCR master mix were added to the
124 respective wells in a 96 well PCR plate. The PCR method was set up as per the manufacturer's
125 protocol on Quantstudio3 (ThermoFisher Scientific, US). The samples were classified as positive
126 or negative based on the Ct values specified by the manufacturer (Supplementary file 1).

127 **Preliminary experiments to optimize alternate RNA extraction method**

128 In preliminary experiments, we evaluated two concepts: a. Heat-shock treatment of NPS
129 samples for direct RT-PCR assay; b. Heat-shock or lysis buffer treatment of NPS samples
130 followed by RNA extraction using limited reagents, followed by RT-PCR assay. An aliquot of
131 NPS sample was subjected to heat-shock treatment using the Hybex Microsample Incubator
132 (Scigene). The NPS samples were subjected to the following conditions: 65° C for 15 minutes;
133 80° C for 5 minutes; 90° C for 5 minutes; 80° C for 1 minute, and 40 µl of the sample was
134 directly processed for RT-PCR assay(7-8). Additionally, the same sample was assessed for RNA
135 extraction using an alternate method. In this method, after the respective heat-shock treatment,
136 300 µl of the sample was processed for nucleic acid precipitation using 300 µl isopropanol,
137 followed by 75% ethanol wash, and finally dissolving the nucleic acid in 50 µl water
138 (isopropanol-ethanol-water). Similarly, 40 µl was used for the RT-PCR assay. In addition to the
139 heat-shock method, we also treated the NPS samples with RBC lysis buffer with (56° C for 5
140 minutes) or without heat-shock treatment, followed by isopropanol-ethanol-water steps.

141 **Clinical sample evaluation using an alternate method**

142 From the above-described pilot studies, the method with the highest sensitivity was chosen for
143 analytical evaluation (sensitivity, specificity, accuracy, and precision) using previously
144 confirmed positive (n=50) and negative (n=20) samples. Also, the limit of detection was
145 determined by absolute quantification RT-PCR analysis.

146

147 **Performance evaluation on CDC RT-PCR method (FDA-EUA)**

148 The Center for Disease Control (CDC) RT-PCR method contains oligonucleotide primers and
149 dual-labeled hydrolysis probes (TaqMan®) and control material for the *in vitro* qualitative
150 detection of SARS-CoV-2 RNA in respiratory specimens
151 (<https://www.fda.gov/media/134919/download>, last accessed June 1, 2020). The oligonucleotide
152 primers and probes for the detection of SARS-CoV-2 target the virus N gene. An additional
153 primer/probe set detects the human RNase P gene (RP) as an internal control. RNA extracted by
154 an alternate method from twenty positive and ten negative samples was evaluated on the CDC
155 RT-PCR assay.

156 **Results**

157 **Preliminary experiments to optimize alternate RNA extraction method**

158 The Ct values were compared between the FDA-EUA approved and alternate methods after RT-
159 PCR. In the first set, NPS samples subjected to heat-shock treatment for direct RT-PCR assay, no
160 amplification/detection of SARS-CoV-2 virus was observed in the four different conditions
161 tested in these groups (65° C for 15 minutes; 80° C for 5 minutes; 90° C for 5 minutes; 80° C for
162 1 minute).

163 In the second set of NPS samples subjected to heat-shock or lysis buffer treatment followed by
164 RNA extraction using limited reagents followed by the RT-PCR assay, SARS-CoV-2 was
165 amplified/ detected in all six different conditions. The Ct value difference of these alternate
166 methods was compared with the Ct values of the FDA-EUA method. The Ct value difference
167 with 65° C for 15 minutes-Isopropanol-Ethanol-Water and Lysis-Isopropanol-Ethanol-Water
168 methods were comparable with each other [(d)Ct N gene= \sim 4, (d)Ct ORF1ab+ \sim 12]. A trend was
169 observed with the different methods, where the Ct value difference decreased with increasing
170 temperature as follows: 65° C for 15 minutes-Isopropanol-Ethanol-Water > 80° C for 5 minutes-
171 Isopropanol-Ethanol-Water > 90° C for 5 minutes-Isopropanol-Ethanol-Water (**Fig 1**). The
172 preliminary results showed that 90° C for 5 minutes-Isopropanol-Ethanol-Water method had the
173 least deviation of Ct value from the original FDA-EUA method and therefore was selected for
174 further evaluation.

175 **Clinical sample evaluation with 90° C for 5 minutes-Isopropanol-Ethanol-Water method**

176 Fifty previously confirmed positive and twenty negative samples were processed for RNA
177 extraction by the alternate method and RT-PCR analysis. Analytical sensitivity of 92%,
178 analytical specificity of 100%, accuracy of 94.2%, and precision of 100% were observed (**Table**
179 **1**). The Ct value difference for both N and ORF1ab genes is depicted in **Fig 2 and 3**. The LOD
180 was determined to be ~40 copies/ml by absolute quantification calculation.

181 **Replicating results on the CDC RT-PCR method (FDA-EUA)**

182 Twenty previously confirmed positive and ten negative samples were processed for RNA
183 extraction by the alternate method and CDC RT-PCR analysis. The results demonstrated a 100%
184 positive and negative percent agreement (**Table 1**) (**Supplementary file 1**).

185 **Discussion**

186 The COVID-19 pandemic has led to an enormous burden on the health care system, to the point
187 of exhausting current resources to manage or contain its spread. In this effort, testing for SARS-
188 CoV-2 has been the most critical measure implemented across the globe. The qualitative RT-
189 PCR based methods for the detection of SARS-CoV-2 have been the primary method for the
190 diagnosis of COVID-19. However, RNA extraction is the most significant rate-limiting step in
191 this protocol because of a wide range of reasons including, competent testing personnel, cost of
192 reagents/ kits, equipment, and turnaround time. In addition to these challenges, supply chain
193 constraints have further disrupted efforts to ramp up testing to effectively test or screen a given
194 population.

195 To reduce the cost and turnaround time, several groups have evaluated various methods that
196 bypass the RNA extraction step using two major categories: collecting dry-swabs directly in a
197 small volume of TE buffer instead of UTM, or aliquotting a small volume of nasopharyngeal
198 swab (NPS) sample for direct RT-PCR for the detection of SARS-CoV-2 (3-6). The dry-swab
199 method does not appear to be a practical method for population screening, as the front-end
200 methodology i.e. sample collection, is difficult to alter because of intangible reasons including
201 current healthcare policies as well as practical concerns around storage, shipping of samples,
202 and stability of virus. Thus, in the present study, we have focused on the approach of altering or
203 bypassing the RNA extraction step from conventional samples i.e. NPS samples.

204 In our pilot studies, we first evaluated the extraction-free RT-PCR methods, where the NSP
205 samples were subjected to different heat-shock treatment (65° C for 15 minutes; 80° C for 5
206 minutes; 90° C for 5 minutes; 80° C for 1 minute), and processed for direct RT-PCR assay.^{7,8}

207 Although, we used samples with low Ct values (via standard initial testing), no amplification/
208 detection was observed at all four temperature conditions. This led us to process samples with an
209 alternate protocol, where after heat-shock treatment, the nucleic acid was precipitated with
210 isopropanol, washed with ethanol, and dissolved in water. Additionally lysis buffer was also
211 assessed as an alternative to heat-shock treatment, followed by isopropanol-ethanol-water steps.
212 Comparing the different heat-shock treatments vs lysis conditions followed by isopropanol-
213 ethanol-water steps, the 90° C for 5 minutes followed by Isopropanol-Ethanol-Water method was
214 found to be most sensitive as it showed Ct values comparable to the FDA-EUA method. Based
215 on this pilot data it is proposed that the 90° C for 5 minutes heat-shock treatment results in more
216 effective lysis of the cells compared to other conditions, and hence sufficient nucleic acid is
217 available for amplification and detection.

218 After establishing the most effective kit-free RNA extraction method, analytical evaluation was
219 conducted on one hundred clinical samples, using two different RT-PCR protocols in the
220 laboratory. Seventy clinical samples were evaluated with PerkinElmer Inc. RT-PCR method,
221 which has demonstrated high analytical sensitivity, specificity, accuracy, and precision. Of the
222 fifty positive clinical samples, three samples with Ct values > 36 on the FDA-EUA method were
223 not detected with our alternate method. The absolute quantification identified an LOD of 40
224 copies/ ml and it is expected that the samples with a viral load <40 copies/ml are expected to
225 yield false-negative results and explains the four samples that did not yield positive results in our
226 analytical evaluation with clinical samples. It is noteworthy that the initial positive results on
227 these 3 samples is attributed to the LoD of 20 copies/mL validated on the PerkinElmer FDA-
228 EUA method in our laboratory. The alternate RNA extraction method was also evaluated with
229 the CDC RT-PCR assay and the overall-results showed a sensitivity of 94.2% and specificity of
230 100%, confirming the practicality of the alternate RNA extraction method.

231 The implementation of this proposed alternate protocol for COVID-19 has the potential to
232 increase SARS-CoV-2 testing, reducing turnaround times, clearing backlogged samples, and
233 ensuring enormous savings on RNA extraction and/or testing kits and laboratory supplies that are
234 in short supply. This would relieve the pressure mounting on laboratories for increased testing,
235 hopefully making a significant contribution to control of this pandemic.

236 **References**

- 237 1. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, Lane HC,
238 Memish Z, Oh MD, Schuchat A, Ungchusak K. 2020. COVID-19: towards controlling of
239 a pandemic. *Lancet* 395(10229): 1015–18.
- 240 2. Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, George KS, Smith TC, Bertuzzi S.
241 2020. Report from the American Society for Microbiology COVID-19 international
242 summit, 23 march 2020: value of diagnostic testing for SARS–CoV-2/COVID-19. *mBio*
243 11(2):e00722-20.
- 244 3. Kiran U, Gokulan CG, Kuncha SK, Vedagiri D, Tallapaka KB, Mishra RK, Harshan K.
245 2020. Improved and Simplified Diagnosis of Covid-19 using TE Extraction from Dry
246 Swabs. *bioRxiv*. <https://doi.org/10.1101/2020.05.31.126342>.
- 247 4. Srivatsan S, Han PD, van Raay K, Wolf CR, McCulloch DJ, Kim AE, Brandstetter E,
248 Martin B, Gehring J, Chen W, Kosuri S. 2020. Preliminary support for a “dry swab,
249 extraction free” protocol for SARS-CoV-2 testing via RT-qPCR. *bioRxiv*
250 <https://doi.org/10.1101/2020.04.22.056283>.
- 251 5. Smyrlaki I, Ekman M, Vondracek M, Papanicoloau N, Lentini A, Aarum J, Muradrasoli
252 S, Albert J, Högberg B, Reinius B. 2020. Massive and rapid COVID-19 testing is feasible
253 by extraction-free SARS-CoV-2 RT-qPCR. *medRxiv*
254 <https://doi.org/10.1101/2020.04.17.20067348>.
- 255 6. Wee SK, Sivalingam SP, Yap EP. 2020. Rapid direct nucleic acid amplification test
256 without RNA extraction for SARS-CoV-2 using a portable PCR thermocycler. *bioRxiv*
257 <https://doi.org/10.1101/2020.04.17.042366>.
- 258 7. Kampf G, Voss A, Scheithauer S. 2020. Inactivation of coronaviruses by heat. *J Hosp*
259 *Infect* 105(2):348-349.
- 260 8. Batéjat C, Grassin Q, Manuguerra JC. 2020. Heat inactivation of the Severe Acute
261 Respiratory Syndrome Coronavirus 2. *bioRxiv*
262 <https://doi.org/10.1101/2020.05.01.067769>.


264 **Table 1.** The performance metric in clinical samples.

Performance Criterion	Performance with PE RT-PCR assay (%)	Performance with CDC RT-PCR assay (%)	Over-all Performance (%)
Positive percentage agreement (PPA) = TP/ (TP+FN)	92	100	94.2
Negative percentage agreement (NPA) = TN/ (TN+FP)	100	100	100
Positive predictive value (PPV) = TP/ (TP+FP)	100	100	100
Negative predictive value (NPV) = TN/ (TN+FN)	83.3	100	88.2
Accuracy = TP+TN/All Results	94.2	100	96
False Negative Rate (FNR) = FN/ (FN+TP)	8	0	5.7
False Positive Rate (FPR) = FP/ (FP+TN)	0	0	0

265

266


267



268
269

270 **Fig 1.** Preliminary experiments to optimize alternate RNA extraction method.


271



272

273 **Fig 2.** The comparison of Ct values for the N gene with PerkinElmer Inc. FDA-EUA method vs. alternate method.

274



275

276

277 **Fig 3.** The comparison of Ct values for the ORF1ab gene with PerkinElmer Inc. FDA-EUA method vs. alternate method.

278